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ABSTRACT
PD-1 is a well-established negative regulator of T cell
responses by inhibiting proliferation and cytokine pro-
duction of T cells via interaction with its ligands,
B7-H1 (PD-L1) and B7-DC (PD-L2), expressed on
non-T cells. Recently, PD-1 was found to be ex-
pressed in innate cells, including activated DCs, and
plays roles in suppressing production of inflammatory
cytokines. In this study, we demonstrate that PD-1 KO
DCs exhibited prolonged longevity compared with WT
DCs in the dLNs after transfer of DCs into hind foot-
pads. Interestingly, upon LPS stimulation, WT DCs in-
creased the expression of PD-1 and started to un-
dergo apoptosis. DCs, in spleen of LPS-injected PD-1
KO mice, were more resistant to LPS-mediated apo-
ptosis in vivo than WT controls. Moreover, treatment
of blocking anti-PD-1 mAb during DC maturation re-
sulted in enhanced DC survival, suggesting that PD-1:
PD-L interactions are involved in DC apoptosis. As a
result, PD-1-deficient DCs augmented T cell re-
sponses in terms of antigen-specific IFN- production
and proliferation of CD4 and CD8 T cells to a greater
degree than WT DCs. Moreover, PD-1 KO DCs exhib-
ited increased MAPK1 and CD40–CD40L signaling,
suggesting a possible mechanism for enhanced DC
survival in the absence of PD-1 expression. Taken to-
gether, our findings further extend the function of
PD-1, which plays an important role in apoptosis of
activated DCs and provides important implications
for PD-1-mediated immune regulation. J. Leukoc. Biol.
95: 621–629; 2014.
Introduction
DCs are professional APCs that are critical for regulation of
immune tolerance, as well as immune activation. Upon en-
countering the foreign antigens with microbial signals, DCs
become matured and activated and carry these antigens to the
regional LNs, where they stimulate the naive T cells to induce
active immune responses. In contrast, under steady-state condi-
tions, DCs in peripheral tissues constitutively uptake self-anti-
gens without being matured and thus, induce peripheral toler-
ance [1, 2]. It has been shown that immature DCs, character-
ized by low expression levels of MHC II and costimulatory
molecules, inhibit effector functions of T cells and protect au-
toimmune encephalitis [3–5], demonstrating that the matura-
tion status of DCs is crucial for their ability to induce tolero-
genic immune responses.
In addition to DC maturation status, DC homeostasis, con-
trolled by apoptosis, plays an important role in the immune
regulation. As a result of the short lifespan of DCs, prolonged
survival of DCs was required to enhance the antigen-specific
immune responses during their interactions with naive T cells
in the LNs. However, once DCs present antigens to T cells,
they need to be eliminated in the LNs to limit the antigen
availability to T cells, thus avoiding the aberrant T cell activa-
tion. Defects in DC apoptosis by deletion of proapoptotic
genes, such as B cell lymphoma-2 interacting mediator of cell
death and Bcl-2 or death receptor Fas could also disrupt the
DC homeostasis and trigger autoimmune diseases [6–8]. In
addition, transfer of excessive amount of DCs induces the de-
velopment of autoimmune diseases [9, 10]. The mechanisms
of how DC apoptosis contributes to the immune regulation are
not yet fully understood, but recent studies have shown that
apoptotic DCs taken up by viable DCs might induce immune
tolerance via generation of regulatory T cells [11, 12].
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PD-1, a member of Ig superfamily, is inducibly expressed on
T and B cells upon activation, which delivers inhibitory signals
in lymphocytes by interacting with its ligands, B7-H1 (PD-L1)
and B7-DC (PD-L2) [13]. PD-1 has significant suppressive ef-
fects on cytokine production, such as IFN-, TNF-, and IL-2,
in T cells by inhibiting PI3K activity [14]. In addition, with-
drawal of IL-2 by PD-1 ligation leads to T cell death [15], and
blockade of PD-1 remarkably regresses tumor growth during
cancer therapy via augmentation of tumor- specific T cell re-
sponses, implying the crucial role of PD-1 in immune toler-
ance [16–18]. It was reported that PD-1 is also induced in
non-T and B cells, such as DCs and macrophages, upon TLR
ligand-mediated stimulation, and its ligation negatively regu-
lates cytokine productions from these cells, including TNF-,
IL-6, IL-12, and MIP-1 [19, 20].
In the present study, we investigate the role of PD-1 in DC
survival in vitro and in vivo. We demonstrated that PD-1 ex-
pressed on DCs plays a role in inducing apoptosis in activated
DCs and that enhanced survival of DCs via PD-1 deficiency
leads to improved antigen-specific CD4 and CD8 T cell re-
sponses. Thus, our results provide a novel function of PD-1 in
the immune regulation by DC survival.
MATERIALS AND METHODS
Mice
Specific pathogen-free B6, B6 Thy1.1 OT-I, B6 Thy1.1 OT-II, B6 RAG-1
KO, and B6 CD45.1 mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA). B6 PD-1 KO mice were obtained from Dr. Tasuku
Honjo (Kyoto University, Japan) via Dr. Sang-Nae Cho (Yonsei University,
Korea). Mice were bred and maintained in the animal facility at the Po-
hang University of Science and Technology Biotech Center (Pohang, Ko-
rea), and age- and sex-matched, 6- to 8-week-old mice were used for all ex-
periments. All mouse experiments were performed in accordance with the
U.S. National Institutes of Health guidelines, and protocols were approved
by the Institutional Animal Care and Use Committee .
Isolation of DCs and T cells
Spleen fragments were digested at 37°C in 10% RPMI 1640 (10% FBS2-
ME), supplemented with 1.5 mg/ml collagenase D and 50 g/ml DNase I
(both from Roche Diagnostics, Indianapolis, IN, USA), for 45 min and
then treated for an additional 5 min with 1 mM EDTA (pH 7.2). CD11c
DCs were isolated by using CD11c microbeads (Milteny Biotec, Auburn,
CA, USA), according to the manufacturer’s instructions. Purified cells
(93%) were CD11c-positive.
OT-I, OT-II, or CD5 cells were isolated by using CD8 and CD4 T cell
isolation kits and CD5 microbeads (Milteny Biotec), according to the man-
ufacturer’s instructions.
In vitro culture of DCs
Cells/ml (2106) of purified CD11c WT (B6) and PD-1 KO DCs from
naive mice were cultured without any stimuli for 24 h. During incubation,
10 g/ml mAb to PD-1 (Clone 29F.1A12; a kind gift from Gordon J. Free-
man at Havard Medical School, Boston, MA, USA) or rat IgG2a as an iso-
type control was treated to block the interaction of PD-1 with its ligands.
In vivo transfer of DCs and LPS injection
Purified DCs from WT and PD-1 KO mice were treated with 0.1 g/ml LPS
(Escherichia coli serotype 0111:B4; Invitrogen, Carlsbad, CA, USA) for 2 h,
and then 1  106 DCs in 50 l vol were injected into footpads of CD45.1
mice. At the indicated time-points after transfer, popliteal LNs were har-
vested for the analysis. For the study to block PD-1 expression on trans-
ferred DCs, DCs from CD45.1 mice were stimulated with LPS and then in-
jected into footpads of RAG-1 KO (CD45.2) mice. Anti-PD-1 mAb (200 g;
Clone J43; Bio X Cell, West Lebanon, NH, USA) or the same amount of
hamster IgG as an isotype control was injected simultaneously. For an ex
vivo imaging experiment, WT and PD-1 KO DCs were labeled with 5 M
CMTMR and 10 M DDAO (both Molecular Probes, Invitrogen), respec-
tively. Fluorescence-labeled WT and PD-1 KO DCs were mixed with a 1:1
ratio, and then 2  106 of the cell mixture was injected s.c. into hind foot-
pads of B6 mice. Forty-eight hours after transfer, DCs within the frozen
sections of fixed popliteal LNs were visualized by a modified Zeiss Axio Ob-
server.Z1 epifluorescence microscope with a 40 (Plan-Neofluar;
NA1.30) objective lens and a Roper Scientific CoolSNAP high-quality
charge-coupled device camera and analyzed using MetaMorph (Molecular
Devices, Downingtown, PA, USA).
For in vivo LPS treatment, mice were injected i.v. with 50 g LPS. Con-
trol mice were treated with the same volume of PBS.
mAb and flow cytometry
Cells were analyzed with a Gallios cytometer (Immunologics; Beckman
Coulter, Brea, CA, USA). Before staining, cells were FcR-blocked with 1 g
purified anti-CD16/32 mAb (2.4G2; eBioscience, San Diego, CA, USA).
The mAb used for staining were allophycocyanin- or eFluor450-conjugated
CD4, allophycocyanin- or PE-Cy7-conjugated CD8, eFluor450-conjugated
Thy1.1, allophycocyanin-conjugated CD45.1, PE-conjugated CD45.2, FITC-
conjugated CD11b, allophycocyanin- or eFluor450-conjugated anti-CD11c,
FITC-conjugated plasmacytoid DC antigen-1, PE-conjugated B220,
eFluor450-conjugated anti-MHC II, FITC-conjugated anti-B7-1, FITC-conju-
gated anti-B7-2, biotin-conjugated anti-B7-H1, FITC-conjugated Annexin-V
and PI, PE-conjugated CD40, and PE-conjugated CD40L (all from eBiosci-
ence); purified ERK2, FITC-conjugated anti-mouse IgG1, and PE-conju-
gated p-ERK1/2 (BD Biosciences, San Diego, CA, USA); and PE-conjugated
anti-PD-1 (Clone RMP1-30) and its isotype control (BioLegend, San Diego,
CA, USA).
T cell simulation
DCs from WT and PD-1 KO mice were pulsed with 10 g/ml OVA257–264
(OT-I, SIINFEKL; synthesized by Peptron, Korea) or OVA323–339 (OT-II,
ISQAVHAAHAEINEAGR; AnaSpec, Fremont, CA, USA) for 2 h. For in
vitro study, 1  105 OT-I or OT-II cells labeled with 1.25 M CFSE were
cultured with OVA peptide-pulsed DCs for 60 h at various DC:T ratios. For
in vivo study, 3  105 OVA peptide-pulsed DCs (0 h) and 1.5  106 OT-I
or OT-II cells (5 h), labeled with 5 M CFSE, were transferred i.v. into
Thy1.2 B6 recipients, and T cell proliferation was examined at 60 h after
T cell transfer.
For in vitro PD-1 blockade experiment, 1  105 PD-1 KO CD5 cells
(pan-T cells) were stimulated by 1  104 WT or PD-1 KO DCs with 1
g/ml anti-CD3 mAb (BD Biosciences) in the presence of 20 g/ml anti-
PD-1 mAb (J43). IFN- production was examined at 60 h.
mRNA purification and quantitative real-time PCR
Total RNA from CD11c splenic DCs of WT or PD-1 KO mice were ex-
tracted by using TRIzol reagent (Invitrogen), and the cDNA was synthe-
sized with random primers (Qiagen, Venlo, Netherlands). The expressions
of apoptosis-related genes were analyzed by SYBR Green-based quantitative
real-time PCR using RT2 Profiler apoptosis PCR array (Qiagen). Gene ex-
pression was normalized to the expression of housekeeping genes
(GAPDH, -actin, and heat shock protein 90).
Statistics
Data are typically shown as mean  sem. The differences between the
groups were assessed using two-tailed Student’s t-test. P  0.05 was consid-
ered statistically significant.
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RESULTS
Enhanced recovery of PD-1-deficient DCs in the dLN
after in vivo transfer
To investigate whether PD-1 plays a role in homeostasis of
DCs, we stimulated WT or PD-1 KO DCs (CD45.2) with LPS in
vitro and then injected them into hind footpads of CD45.1
recipient mice. The DCs recovered in dLNs were assessed by
analyzing CD45.2 CD11c populations. As shown in Fig. 1A,
by 2 days after transfer, more fractions of PD-1 KO DCs were
detected in dLNs compared with WT DCs. The number of WT
or PD-1 KO DCs in dLNs peaked at 2 days after transfer and
then decreased gradually and became undetectable on Day 7
(Fig. 1B). Interestingly, the average number of accumulated
PD-1 KO DCs in the dLNs was significantly higher than that of
WT DCs on Day 2. Consistently, accumulation of WT DCs was
increased by injection of anti-PD-1 mAb (Supplemental Fig. 1).
We observed that the expression of CCR7, an important
chemokine receptor for migration of DCs to the dLN, was sim-
ilar between two DCs (Fig. 1C), suggesting that increased re-
covery of PD-1 KO DCs in the dLN compared with WT DCs
was not a result of the enhanced migration capacity of
these DCs.
For the in situ visualization of WT and PD-1 KO DCs in the
dLN after DC transfer, we labeled WT and PD-1 KO DCs with
cell-tracker dyes and then coinjected them into the same foot-
pad of B6 recipients. Consistently, fewer CMTMR-labeled WT
DCs were detected than DDAO-labeled PD-1 KO DCs in frozen
sections of the dLN (Fig. 2). Similar results were also obtained
when cell-tracker dyes were switched (data not shown), indicat-
ing that these dyes did not affect the viability of DCs. Taken
together, these data suggest that PD-1 expression on DCs is
involved in the negative regulation of DC survival in vivo.
PD-1 induced by DC activation is involved in DC
apoptosis after LPS administration
When we compared in vitro, spontaneous apoptosis between
WT and PD-1 KO DCs, PD-1 KO DCs were less apoptotic com-
pared with WT DCs, by 11% (Fig. 1D; Untreated). This re-
sult coincides with the PD-1-expressing DC populations, which
are 10–20% in the same in vitro culture condition (data not
shown). When WT DCs were treated with anti-PD-1 mAb,
which block interactions of PD-1 with its ligands, such as
B7-H1 and B7-DC, the apoptosis of WT DCs were abrogated to
the level analogous with untreated PD-1 KO DCs (from
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Figure 1. PD-1 deficiency ren-
ders longevity of DCs in vivo.
(A and B) Splenic DCs from
WT (B6, CD45.2) or PD-1 KO
(CD45.2) mice were stimu-
lated with LPS for 2 h and
then injected into footpads of
B6 CD45.1 recipients. On 1, 2,
3, and 7 days after injection,
the fraction of transferred DCs
(CD11c CD45.2) in dLNs
was examined by flow cytom-
etry. (A) Transferred DC pop-
ulations of WT or PD-1 KO
mice among the PI-negative
LN cells of the recipient mice were shown on 1, 2, and 7 day after DC transfer. SSC, Side-scatter. (B) Absolute cell numbers of transferred
DCs in the dLN of recipients were analyzed at each time-point. The values on dots indicate mean  sem of three mice/group. Data are
representative of four independent experiments with similar results. *P  0.05 versus WT controls by Student’s t-test. (C) CCR7 expres-
sion in WT and PD-1 KO DCs after LPS stimulation. DCs treated with LPS for 2 h were washed more than three times and were incubated
further for 24 h. Before (2 h) and after (24 h) the additional incubation, the expression of CCR7 on DCs was analyzed. Representative
histograms from three independent experiments were shown. (D) Purified WT and PD-1 KO DCs were incubated with 10 g/ml anti-PD-1
mAb or rat IgG2a as a control. At 24 h after incubation, binding of Annexin-V was analyzed by flow cytometry. The values on bars indicate
percent (meansd) of Annexin-V-positive cells. Data are representative of more than three independent experiments with similar results.
**P  0.005 by Student’s t-test.
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33.30.81% to 21.92.18%). As expected, the apoptosis of
PD-1 KO DCs was unaffected by antibody treatment (Fig. 1D).
This result suggests that PD-1 mediates apoptosis of PD-1-ex-
pressing DCs via interaction with its ligands.
To investigate the in vivo role of PD-1 in DC survival, LPS
was administrated systemically, which is a well-established
model to study the maturation and apoptosis of DCs in vivo
[21, 22]. As noted, WT and PD-1 KO DCs showed a highly ac-
tivated phenotype after LPS injection, including B7-1, B7-2,
and B7-H1, with no significant differences between them
(Fig. 3A). As DC activation by TLR ligation is reported to in-
duce PD-1 expression in vitro [23], we also examined the ex-
pression pattern of PD-1 on DCs after LPS administration. En-
hanced PD-1 expression on WT DCs but not on PD-1 KO DCs
was accompanied by LPS-mediated activation of these cells
(Fig. 3B). As shown in Fig. 3C, the percentage of PD-1-express-
ing DCs in spleens of WT mice reached its peak (12% of
splenic DCs) at 20 h after LPS injection and then decreased
gradually to a basal level at 48 h. Interestingly, the number of
apoptotic DCs assessed by Annexin-V binding was highest at 32
h after LPS injection, which is 12 h after the peak expression
of PD-1. This result suggests that induction of PD-1 expression
might be a prerequisite for the apoptosis of DCs. Interestingly,
there were significantly higher fractions of DCs in PD-1 KO
mice (0.920.09%) compared with WT DCs (0.490.05%)
after LPS administration, whereas naive, untreated WT and
PD-1 KO mice showed similar DC populations in spleens.
Moreover, the average number of DCs from LPS-injected PD-1
KO mice was significantly higher than WT controls (Fig. 3D).
We confirmed further that a higher number of splenic DCs in
PD-1 KO mice injected with LPS were concomitant with a
lower level of DC apoptosis, as assessed by Annexin-V binding
(Fig. 3E). Taken together, our results suggest that inducible
PD-1 on DCs plays an important role in regulating apoptosis
of activated DCs.
Correlation of PD-1 deficiency with up-regulation of
MAPK1 pathway and CD40–CD40L interactions
To investigate signaling molecules involved in PD-1-mediated
apoptosis of activated DCs, we analyzed the mRNA level of ap-
optosis-related genes in WT and PD-1 KO DCs. Among the
genes analyzed, Mapk1 (ERK2) and Cd40lg (CD40L, CD154)
mRNA levels, which are well-known pathways involved in DC
survival, were decreased significantly in WT DCs of mice in-
jected with LPS compared with naive WT controls, whereas
they were up-regulated (Mapk1) or not changed (Cd40lg) in
PD-1 KO DCs after LPS injection (Fig. 4A). As a result, relative
fold changes of Mapk1 and Cd40lg mRNA in PD-1 KO DCs
were 10 and 140 times higher, respectively, than those in WT
DCs after LPS administration (Fig. 4B). Consistently, the per-
centages of CD40, CD40L, ERK2, and p-ERK1/2 expression
were significantly higher in PD-1 KO DCs than those of WT
DCs [56.14.0% vs. 34.53.2%; 25.31.0% vs. 19.22.3%;
95.43.1% vs. 61.53.5%; and 60.33.7% vs. 45.42.5%, re-
spectively (Fig. 4C)]. This result suggests that down-regulation
of the MAPK1 signaling pathway and CD40–CD40L interaction
might be involved in PD-1-mediated DC apoptosis.
PD-1-deficient DCs elicit higher antigen-specific T cell
responses than WT DCs
To investigate whether increased survival of PD-1 KO DCs
leads to enhanced immune responses, WT or PD-1 KO DCs
pulsed with OVA peptides were cocultured with OT-II OT-I T
cells. The peptide-pulsed PD-1 KO DCs induced higher anti-
gen-specific IFN- production (Fig. 5A) and proliferation (Fig.
5B) in OT-I and OT-II cells in vitro. Consistently, blockade of
PD-1 on WT DCs up-regulated IFN- production in T cells
(Supplemental Fig. 2). This capacity of PD-1 KO DCs to en-
hance T cell responses might not be attributed to the different
DC subsets in PD-1 KO mice, as similar DC subsets were ob-
served in PD-1 KO mice when compared with WT (Supple-
mental Fig. 3). To confirm these results further in vivo, we
stimulated in vivo-transferred OT-I or OT-II cells labeled with
CFSE by injecting OVA-pulsed WT or PD-1 KO DCs. At 60 h
after T cell transfer, we examined proliferation of T cells in
LNs (Fig. 5C) and spleens (Fig. 5D) of recipient B6 mice.
Consistent with in vitro results, OVA-specific CD4 and CD8 T
cells highly proliferated when stimulated by PD-1 KO DCs
compared with WT DCs. These results suggest that DCs with-
out PD-1 expression elicited antigen-specific T cell responses
to a greater degree than WT DCs. Thus, PD-1 blockades might
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Figure 2. Enhanced DC recovery in the absence of PD-1. (A and B)
LPS-stimulated DCs were labeled with 5 M CMTMR (WT) or 10 M
DDAO (PD-1 KO), mixed with a 1:1 ratio, and injected into footpads
of B6 mice. At 48 h after injection, transferred DCs within the frozen
sections of fixed dLNs were visualized by the MetaMorph system. (A)
Representative image of more than three dLNs. Arrows indicate the
population of transferred DCs. (B) The values on bars indicate the
mean percent  sem of WT or PD-1 KO DCs among the total trans-
ferred DCs in each dLN. Data are representative of two independent
experiments (n3/group).
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be needed to enhance antigen-specific T cell responses, in-
cluding cytokine production and proliferation, in the DC-
based vaccination.
DISCUSSION
The roles of DCs in the adaptive immune responses start with
antigen uptake and presentation to T cells and end by apopto-
sis afterward. As DCs are the initiators and regulators of im-
mune responses, their lifecycle should be tightly controlled.
Indeed, activated DCs, which stimulated T cells in lymphoid
organs, undergo apoptosis rapidly [24–27]. Although the im-
munoinhibitory roles of PD-1 expressed on T cells have been
studied extensively over the last decade, PD-1 expression and
its functions in DCs have not been well addressed yet. Here,
we provide the first evidence that PD-1 induces apoptosis of
matured DCs.
Apoptosis of DCs after antigen presentation is an important
mechanism to regulate immune responses. During antigen
presentation to T cells, DCs receive survival or apoptotic sig-
nals from the interacting T cells. Ligation of Fas (CD95), ex-
pressed on maturated DCs with its Fas ligand (CD95L) on acti-
vated T cells, results in DC apoptosis via up-regulation of cellu-
lar FLICE-like inhibitory protein, long isoform [28], and MHC
II induces apoptosis of DCs by inhibiting PKC during interac-
tion with T cells [24]. MHC II is also responsible for DC apo-
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Figure 3. PD-1 deficiency reduces apoptosis of activated DCs. WT or PD-1 KO mice were i.v.-injected with 50 g LPS (LPS-positive) or PBS as a
control. At 24 h (A, B, and D) or indicated time-points (C and E) after LPS injection, DCs in spleens were analyzed by flow cytometry. Expression
of (A) B7-1, B7-2, and B7-H1 and (B) PD-1 on the CD11c MHC II population in spleen was examined. (C) PD-1 fractions or Annexin-V bind-
ing [mean fluorescence intensity (MFI)] in WT DCs in spleens were analyzed at the indicated time-points after LPS injection. The values on dots
indicate mean  sem (n3/each time-point). (D) DC population in the spleens of WT or PD-1 KO mice after LPS treatment was analyzed by flow
cytometry. Absolute numbers of DCs in the spleens were shown in the dot graphs (lower panel), and each dot represents a single mouse. (E)
Binding of Annexin-V was examined in WT or PD-1 KO DCs at indicated time-points after LPS injection. The values on bars indicate mean fluo-
rescence intensity  sem of three or four mice. Data are pooled from two independent experiments. *P  0.05; **P  0.01 versus WT controls, by
Student’s t-test.
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ptosis in homotypic DC–DC interactions by activating caspase-3
and -9 [29]. On the other hand, the CD40–CD40L interaction
protects DCs from the apoptosis via activation of Akt1 [30].
The RANK–RANKL interaction increases the survival of DCs
during DC–T cell interactions via activation of antiapoptotic
signaling initiated by NF-	B and JNK pathways and Bcl-xL up-
regulation [31, 32]. Our findings in this study propose an ad-
ditional mechanism for DC apoptosis: that PD-1 ligation in-
duces DC apoptosis. As two ligands of PD-1 (B7-H1 and B7-
DC) are expressed on DCs and T cells [33, 34], either the
DC–T cell or DC–DC interaction might contribute to PD-1-
mediated DC apoptosis. It is likely that PD-1 might not be in-
volved in the apoptosis of immature DCs as a result of the ab-
sence of PD-1 expression under steady-state. However, PD-1-
mediated DC apoptosis might play a role in the DC
elimination process after antigen presentation, as PD-1 expres-
sion is induced on DCs only after their activation, and DC apo-
ptosis starts to increase after PD-1 up-regulation (Fig. 3).
PD-1 expression in T cells and DCs is regulated by the dis-
tinct pathway. Whereas PD-1 expression is induced by TCR
activation in T cells [15], it is regulated through TLRs in DCs
[23]. However, PD-1 downstream signaling appears to be uni-
versal in each subset of immune cells. PD-1 engagement on T
cells inhibits the TCR downstream PI3K-Akt-NF-	B pathway,
which results in the down-regulation of cytokine production
and proliferation [14]. Similarly, several reports on the PD-1
signaling pathway in innate-immune cells have shown that
PD-1 inhibits NF-	B activation, leading to the down-regulation
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Figure 4. MAPK1 pathway and CD40–CD40L
interaction are involved in PD-1-mediated apo-
ptosis of DCs. At (A and B) 24 h or (C) 14 h
after i.v. injection of PBS (naive) or LPS (LPS-
positive), total RNA from CD11c splenic DCs
of WT or PD-1 KO mice was extracted. (A) Re-
sults are relative level of each gene in DCs from
LPS-treated mice to the naive control (up-regu-
lation: black; down-regulation: white), and WT
versus PD-1 KO mice. (A, a) WT, LPS () to
naive; (A, b) PD-1 KO, LPS () to naive; (A, c)
LPS (), WT to PD-1 KO. The genes changed
more than threefold were shown. Trp, transfor-
mation related protein; Tnfsf, TNF superfamily;
Polb, DNA polymerase beta; Dffb, DNA fragmen-
tation factor subunit beta; Cideb, cell death-in-
ducing DFFA-like effector b; Casp, caspase; Bnip,
BCL2/adenovirus E1B 19 kDa protein-interact-
ing protein 2. (B) Log3 fold change in the rela-
tive level of the genes in DCs from LPS-treated
mice to the naive control (white bar: WT; gray
bar: PD-1 KO) and DCs from WT versus PD-1
KO were shown (black bar). Data are pooled
from at least five mice/group and representative
of two different experiments. (C) Expression of
CD40, CD40L, ERK2, and p-ERK1/2 in WT DCs
and PD-1 KO DCs from LPS-injected mice. Num-
bers in plots indicate percent of WT (black) and
PD-1 KO DCs (red) expressing each molecule.
Data are representative of three different experi-
ments with similar results (n3).
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of inflammatory cytokines, such as IL-12 and TNF- in macro-
phage RAW264.7 cells and tumor-infiltrating DCs [20, 35]. We
observed that expressions of ERK2, CD40, and CD40L were
higher in PD-1 KO DCs than those in WT DCs after LPS injec-
tion (Fig. 4). The CD40–CD40L interaction is recognized to
be activated by TLR4 ligation in innate-immune cells [36], and
both TLR4 and CD40–CD40L ligation induces activation of
MAPK1 signaling, which is required for DC survival [37–39].
Consistent with our data, it has been reported previously that
PD-1 ligation with its ligand inhibits not only the PI3K-Akt
pathway but also the MAPK1 pathway in human T cells acti-
vated with anti-CD3
 mAb [40]. Another study has also shown
that blockade of PD-1 and B7-H1 interaction rescues ex-
hausted CD8 T cells via up-regulation of the CD40–CD40L
ligation pathway [41]. Taken together, these results suggest
that downstream of PD-1, in T cells and DCs, is regulated by
the common signaling pathways; PD-1 induced in DCs, as well
as T cells, acts as a negative-feedback mechanism for the main-
tenance of immune homeostasis.
It has been reported that various types of tumor cells ex-
press B7-H1, which gives immunosuppressive signals to tumor-
infiltrating T cells expressing PD-1, thus inhibiting anti-tumor
activity of T cells [42, 43]. Little is known about the role of
PD-1 expressed on DCs in the tumor immunity. However, a
recent report showed that tumor-associated DCs that express
PD-1 inhibited T cell proliferation and activation in ovarian
cancer via down-regulation of NF-	B activation, cytokine pro-
duction, and costimulatory molecule expressions [35]. Our
study, demonstrating PD-1-mediated DC apoptosis with its neg-
ative effects on T cell responses, further supports the role of
PD-1 on DCs, which contributes the immunosuppressive tumor
environments. Thus, our results provide a novel mechanism
that in addition to PD-1-mediated inhibition of cytokine pro-
ductions in DCs, PD-1-mediated DC apoptosis might play a
role in the immune suppression in cancer.
DC manipulation has been applied to various DC-based vac-
cination or immunotherapies for cancers and other infectious
diseases in mouse models and human clinical trials [44–47].
(-) 1:2 1:10
0
100
200
300
400
WT PD-1 KO
N.D.N.D.
*
 DC : OT-II
IF
N
-
 (
p
g
/m
l)
(-) 1:2 1:10
0
2000
4000
6000
8000
10000
N.D.
**
**
 DC : OT-I
A B
C D
CFSE 
(-) DC (+) WT DC (+) PD-1 KO DC 
OT-II 
OT-I 
0.3  0.0 4.5  0.6  21.9  5.8 
3.2  0.7 48.0  2.6  63.4  1.8 
(-) DC (+) WT DC (+) PD-1 KO DC 
CFSE 
OT-II 
OT-I 
2930  7.2 
2303  31.0  
1155  89.0  459  25.5 
610  20.8 367  35.8 
CFSE 
(-) DC (+) WT DC (+) PD-1 KO DC 
OT-II 
OT-I 
5.3  0.5 10.9  0.7  37.5  1.4 
6.4  0.5 12.9  8.9 70.9  
 2.3 
Figure 5. PD-1 KO DCs augment antigen-specific T cell responses. (A and B) Thy1.1 OT-I or Thy1.1 OT-II cells were stimulated with CD11c
WT or PD-1 KO DCs, pulsed with OVA257–264 or OVA323–339 peptides at an indicated DC:T ratio. (A) IFN- production in the culture supernatants
was measured at 60 h by ELISA. The values on bars indicate mean  sd of triplicated samples. N.D., Not detected. *P  0.05; **P  0.001 versus
WT, by Student’s t-test. Data are representative of two independent experiments with similar results. (B) CFSE dilution in OT-II and OT-I cells,
cultured with or without DCs (DC:T1:10) for 60 h. Numbers on histograms indicate mean percent  sd of CFSElow cells. Data are representative
of two independent experiments with similar results. (C and D) OVA-pulsed DCs (0 h; 3105) and 1.5  106 Thy1.1 OT-I or Thy1.1 OT-II cells
(5 h) were transferred i.v. into Thy1.2 B6 recipients. At 60 h after T cell transfer, proliferation of Thy1.1 OT-II or Thy1.1 OT-I T cells in in-
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CFSElow cells; (D) mean fluorescence intensity of CFSE. Representative data from two independent experiments are shown (n3–5/group).
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As DCs are key players in regulating the magnitude of T cell
responses, studies on the regulation of DC apoptosis by PD-1
and other molecules might improve the efficacy of DC-based
immunotherapies. In conclusion, our findings provide a novel
mechanism for PD-1-mediated immune regulation that PD-1
negatively modulates the survival of DCs. In concert with PD-1-
mediated inhibition of DC functions, as well as T cell effector
functions, our study has important implications for our under-
standing of immune regulations by PD-1 in the adaptive immu-
nity and gives new insights into identifying new targets for the
design of DC-based vaccinations.
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